Sara Brown
Community Health · Riverside, RINPI 1902823909
Payments from drug & device makers
Across 172 payments — averaging $41.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Johnson & Johnson$867
- Biohaven Pharmaceuticals, Inc.$673
- Boehringer Ingelheim$651
- Novo Nordisk$648
- AstraZeneca$447
- plus $3K from 18 others
What the payments were for
- Food & beverage$7,129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $1,156 |
| Johnson & Johnson(2 entities) | 20 | $867 |
| Biohaven Pharmaceuticals, Inc. | 12 | $673 |
| Boehringer Ingelheim | 9 | $651 |
| Novo Nordisk | 16 | $648 |
| AstraZeneca | 11 | $447 |
| Sanofi-aventis U.S. LLC | 13 | $365 |
| AbbVie(2 entities) | 15 | $340 |
| Lilly USA, LLC | 4 | $330 |
| Amgen | 3 | $322 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $258 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $203 |
| Abbott | 2 | $163 |
| Bayer | 3 | $161 |
| Pfizer | 9 | $149 |
| Mylan Specialty L.p. | 2 | $109 |
| Novartis | 5 | $96 |
| Merck | 4 | $59 |
| Amarin Pharma, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$686
- TRELEGY ELLIPTA$350
- NURTEC ODT$346
- XARELTO$343
- XIFAXAN$243
- Ozempic$226
- RYBELSUS$217
- Otezla$213
- FREESTYLE LIBRE 3$143
- AREXVY$125
- Kerendia$124
- FARXIGA$113
- Repatha$109
- TOUJEO$109
- BREZTRI$107
How this compares
Too few community health providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.